Breast Cancer | Specialty

Integrating PARP Inhibitors Into the Treatment of Women

December 30th 2018

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Future Roles of PARP Inhibition in Breast Cancer

December 28th 2018

PARP/Checkpoint Inhibition in TNBC: The TOPACIO Trial

December 28th 2018

Adding Olaparib to Chemotherapy in TNBC: The PARTNER Trial

December 28th 2018

PARP Inhibition as Neoadjuvant Therapy in Breast Cancer

December 28th 2018

A PARP/I-O Strategy in Breast Cancer: The MEDIOLA Trial

December 28th 2018

Proton Beam RT in Breast Cancer Provides Benefit, But More Research Required

December 19th 2018

Kimberly S. Corbin, MD, sheds light on the use of proton radiation therapy in the breast cancer space and which patients may benefit from this approach.

Expert Discusses Lymphedema Treatment and Challenges in Breast Cancer

December 18th 2018

Oscar J. Manrique, MD, discusses the current treatments for patients with lymphedema who have breast cancer and the challenges that remain in this space.

Dr. Borgen on Removing Opioids from Surgical Oncology

December 18th 2018

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses a plan to remove opioids from surgical oncology and the treatment of breast cancer.

Less Invasive Techniques Transform Surgical Management of Breast Cancer

December 17th 2018

Judy C. Boughey, MD, discusses the surgical management of the axilla in patients with node-positive breast cancer and less invasive approaches for disease management.

Expert Addresses Controversies in Management of HR+ Early-Stage Breast Cancer

December 16th 2018

Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events.

Dr. Schmid on the Design and Findings of the KEYNOTE-173 Trial in TNBC

December 14th 2018

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the phase Ib study of pembrolizumab (Keytruda) in combination with chemotherapy for patients with triple negative breast cancer (TNBC).

Dr. O'Regan on Future of Chemotherapy in Breast Cancer

December 11th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

CDK4/6 Inhibitors Are Transforming Treatment in HR+ Breast Cancer

December 11th 2018

Terry L. Evans, MD, discusses the impact of CDK4/6 inhibitors in the metastatic breast cancer space and challenges that still need to be addressed.

TAILORx Analysis Underscores Racial Disparity in Breast Cancer Outcomes

December 11th 2018

African-American patients with early breast cancer had worse outcomes than Caucasian patients following adjuvant therapy, despite having a similar risk of recurrence and receiving similar types of therapy, according to subgroup analysis of the phase III TAILORx trial.

TAILORx Update Shows Different PRO Profiles for Chemo, Endocrine Therapy for Breast Cancer

December 10th 2018

Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.

CAR T-Cell Therapy Shows Early Potential in TNBC

December 8th 2018

Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.

Telephone-Based Lifestyle Interventions Improved Breast Cancer Outcomes

December 8th 2018

Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.

Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer

December 8th 2018

The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.

Breast Cancer Surgery Choice May Affect Quality of Life in Younger Patients

December 8th 2018

Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.